



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
23.08.2023 Bulletin 2023/34

(45) Date of publication and mention
of the grant of the patent:
05.10.2022 Bulletin 2022/40

(21) Application number: **21176545.8**

(22) Date of filing: **02.12.2009**

(51) International Patent Classification (IPC):
A61K 47/68 ^(2017.01) **A61P 35/00** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
A61K 47/6803; A61K 31/4745; A61K 45/06;
A61K 47/6841; A61K 47/6849; A61K 47/6851;
A61K 47/6853; A61K 47/6859; A61K 47/6889;
A61P 17/00; A61P 29/00; A61P 31/00;
A61P 31/04; A61P 31/12; A61P 31/18; (Cont.)

(54) **IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE**
IMMUNKONJUGATE MIT EINER INTRAZELLULÄR SPALTBAREN KOPPLUNG
IMMUNOCONJUGUÉS COMPORTANT UNE LIAISON INTRACELLULAIRE CLIVABLE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR

(30) Priority: **13.02.2009 US 207890 P**

(43) Date of publication of application:
24.11.2021 Bulletin 2021/47

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
18200201.4 / 3 470 087
17178086.9 / 3 243 527
09840166.4 / 2 396 036

(73) Proprietor: **Immunomedics, Inc.**
Morris Plains, NJ 07950 (US)

(72) Inventors:
• **GOVINDAN, Serengulam**
Morris Plains, 07950 (US)
• **MOON, Sung-Ju**
Morris Plains, 07950 (US)
• **GOLDENBERG, David M**
Morris Plains, 07950 (US)

(74) Representative: **Carpmaels & Ransford LLP**
One Southampton Row
London WC1B 5HA (GB)

(56) References cited:
WO-A1-2004/054622 WO-A2-2007/112193
WO-A2-2008/088658 US-A1- 2008 166 363

- **SUNG-JU MOON ET AL: "Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 21, 22 October 2008 (2008-10-22), pages 6916-6926, XP055044282, ISSN: 0022-2623, DOI: 10.1021/jm800719t**
- **T. M. CARDILLO ET AL: "Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys", CLINICAL CANCER RESEARCH, vol. 17, no. 10, 3 March 2011 (2011-03-03), pages 3157-3169, XP055398728, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2939**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

(52) Cooperative Patent Classification (CPC): (Cont.)

A61P 35/00; A61P 35/04; A61P 37/02;
A61P 37/06; C07D 491/22; C07K 16/1063;
C07K 16/2803; C07K 16/2833; C07K 16/2863;
C07K 16/30; A61K 2039/505; Y02A 50/30